PARP1 and ovarian carcinoma: The higher prevalence of HRD in ovarian cancer patients in Asia (including Japan and China) means the more patients who can benefit from PARP inhibitors, which may affect the treatment plan or possibly modifications in treatment guidelines in these patient group.